Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches

Noncovalent DNA interactions, e.g., DNA intercalation and DNA groove‐binding, have not been well studied relative to covalent interactions largely due to the inability of predicting and detecting such events in intact cells. We have adapted an in vitro bleomycin amplification method for DNA intercalation for use in cultured V79 Chinese hamster cells and have validated this approach through the use of a three‐dimensional DNA computational docking model that quantifies potential strength of DNA intercalative binding based on electrostatics and hydrogen bonding. For many structural classes of molecules, DNA intercalation is necessary but not sufficient for genotoxicity. The present article reviews our progress to date in predicting and confirming noncovalent binding of drugs and other chemicals and in understanding the mechanistic relationship between intercalation and genotoxicity. Environ. Mol. Mutagen., 2005. © 2005 Wiley‐Liss, Inc.

[1]  Ronald D Snyder,et al.  Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell‐based and three‐dimensional computational approaches , 2004, Environmental and molecular mutagenesis.

[2]  R. Snyder,et al.  Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.

[3]  Neal F. Cariello,et al.  Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive Estimate of Risk from Existing Knowledge. Toxicity Prediction by Komputer Assisted Technology. , 2002, Mutagenesis.

[4]  Ronald D Snyder,et al.  Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. , 2002, Mutation research.

[5]  Nigel Greene,et al.  Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.

[6]  R. Snyder,et al.  EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLS , 2002, Drug and chemical toxicology.

[7]  Ronald D Snyder,et al.  Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cells , 2002, Environmental and molecular mutagenesis.

[8]  M. Braña,et al.  Intercalators as anticancer drugs. , 2001, Current pharmaceutical design.

[9]  V. Steele,et al.  Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. , 2000, European journal of cancer.

[10]  P Vineis,et al.  Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.

[11]  R. Snyder,et al.  The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. , 2000, Mutagenesis.

[12]  R. Snyder,et al.  Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical‐induced clastogenicity in Chinese hamster V79 cells , 2000, Environmental and molecular mutagenesis.

[13]  L. Strekowski,,et al.  Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. , 1999, Mutation research.

[14]  E. D. Bransome,et al.  The ligand insertion hypothesis in the genomic action of steroid hormones 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  W. Denny,et al.  The mutagenic properties of DNA minor-groove binding ligands. , 1996, Mutation research.

[16]  P. Mosesso,et al.  Report from working group on in vitro tests for chromosomal aberrations. , 1994, Mutation research.

[17]  J. Lown,,et al.  Minor‐groove binders are inhibitors of the catalytic activity of DNA gyrases , 1993, FEBS letters.

[18]  L. EdwardsMichael,et al.  Synthesis and DNA-binding properties of polyamine analogues. , 1991 .

[19]  L. Strekowski,,et al.  Quantitative structure-activity relationship analysis of cation-substituted polyaromatic compounds as potentiators (amplifiers) of bleomycin-mediated degradation of DNA. , 1991, Journal of medicinal chemistry.

[20]  R. L. Jones,et al.  The interaction of unfused polyaromatic heterocycles with DNA: intercalation, groove-binding and bleomycin amplification. , 1990, Anti-cancer drug design.

[21]  W. Denny.  DNA-intercalating ligands as anti-cancer drugs: prospects for future design. , 1989, Anti-cancer drug design.

[22]  M. McHugh,et al.  Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole. , 1989, Molecular pharmacology.

[23]  L. Strekowski,,et al.  Binding of unfused aromatic cations to DNA. The influence of molecular twist on intercalation , 1988 .

[24]  L. Strekowski,,et al.  Molecular basis for bleomycin amplification: conformational and stereoelectronic effects in unfused amplifiers. , 1988, Journal of medicinal chemistry.

[25]  L. Strekowski,,et al.  Amplification of bleomycin-mediated degradation of DNA. , 1987, Journal of medicinal chemistry.

[26]  J. Ashby.  Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. , 1985, Environmental mutagenesis.

[27]  L. Ferguson,et al.  Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. , 1984, Cancer research.

[28]  W. Denny,et al.  Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity. , 1979, Journal of medicinal chemistry.

[29]  L. Hendry,et al.  Gene Regulation: The Involvement of Stereochemical Recognition in DNA-Small Molecule Interactions , 2015, Perspectives in biology and medicine.